Parsippany, NJ, October 11, 2018 – Despite ongoing efforts to end America’s opioid crisis, patients continue to receive large quantities of opioids for postsurgical pain. New research shows that patients received nearly 100 to 200 opioid pills to help manage pain from f... Read more
Pharmacy
New Research Reveals Potency and Quantity of Opioids Prescribed for Postsurgical Pain Poses Danger to Patients, their Families and Friends
Parsippany, NJ, October 11, 2018 – Despite ongoing efforts to end America’s opioid crisis, patients continue to receive large quantities of opioids fo... Read more
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
COLUMBUS, OH (Oct. 9, 2018) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercializatio... Read more
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
Basel, October 08, 2018 – Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have... Read more
Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia
Boston, USA and London, UK, October 04, 2018 / B3C newswire / — Orchard Therapeutics, a leading commercial-stage biotech company dedicated to tr... Read more
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Basel, Switzerland, October 3, 2018 – Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuti... Read more
Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe
ABBOTT PARK, Ill., Oct. 1, 2018 /PRNewswire/ — People living with diabetes in Europe will now have the choice to be alerted in real-time of hypo... Read more
